doi:10.3969/j.issn.1004-583X.2023.02.017

Abstract

CLC Number:

R742.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.02.017

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I2/189

References 35

[1]	Usman S, Anthony EL, Mario M. Neuroimaging advances in Parkinson's disease and atypical Parkinsonian syndromes[J]. Front Neurol, 2020, 15(11):572976.
[2]	Rose BC, Liliana M, Bradford C, et al. Basal and evoked neurotransmitter levels in Parkin,DJ-1,PINK1 and LRRK2 knockout rat striatum[J]. Neuroscience, 2019, 15(409):169-179.
[3]	Onur S, Nese O, Mehmet FO. Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease[J]. Ideggyogy Sz, 2022, 75(2):39-49. doi: 10.18071/isz.75.0039 URL
[4]	Huang ST, Dong YC, Zhao JY. The mean kurtosis (MK) is more sensitive diagnostic biomarker than fractional anisotropy (FA) for Parkinson's disease: A diagnostic performance study and meta-analysis[J]. Medicine (Baltimore), 2022, 101(45):e31312. doi: 10.1097/MD.0000000000031312 URL
[5]	Silvia LP. Diffusion tensor imaging (DTI)[J]. Methods Mol Biol, 2018, 1718:103-116.
[6]	Zhang Y, Marc AB. Corrigendum: Diffusion tensor imaging in Parkinson's disease and Parkinsonian syndrome: A systematic review[J]. Front Neurol, 2020, 11:612069. doi: 10.3389/fneur.2020.612069 URL
[7]	Woo S, Byung J, Sung B, et al. Current clinical applications of diffusion-tensor imaging in neurological disorders[J]. J Clin Neurol, 2018, 14(2):129-140. doi: 10.3988/jcn.2018.14.2.129 pmid: 29504292
[8]	Hamed M, Saman S, Ebrahim K, et al. Probiotics and the treatment of Parkinson's disease: An update[J]. Cell Mol Neurobiol, 2022, 42(8):2449-2457. doi: 10.1007/s10571-021-01128-w
[9]	Tuva RH, Per S, Irena R, et al. Diffusion tensor and restriction spectrum imaging reflect different aspects of neurodegeneration in Parkinson's disease[J]. PLoS One, 2019, 14(5):0217922.
[10]	Shang SA, Li DX, Tian YY, et al. Hybrid PET-MRI for early detection of dopaminergic dysfunction and microstructural degradation involved in Parkinson's disease[J]. Commun Biol, 2021, 4(1):1162. doi: 10.1038/s42003-021-02705-x pmid: 34621005
[11]	Domínguez-Chávez CJ, Murrock CJ, Salazar-González BC. Mild cognitive impairment: A concept analysis[J]. Nurs Forum, 2019, 54(1):68-76. doi: 10.1111/nuf.12299 pmid: 30261109
[12]	Jennifer G, Erica S. Cognitive impairment and dementia in Parkinson disease[J]. Clin Geriatr Med, 2020, 36(2):365-377. doi: S0749-0690(20)30001-X pmid: 32222308
[13]	高亚军, 刘峰, 高晓嵘. 脑白质微结构改变与帕金森病认知功能损害的相关性[J]. 陕西医学杂志, 2016, 45(4):448-449.
[14]	Matsui H, Nishinaka K, Oda M, et al. Dementia in Parkinson's disease: Diffusion tensor imaging[J]. Acta Neurol Scand, 2007, 116(3):177-181. doi: 10.1111/j.1600-0404.2007.00838.x pmid: 17714331
[15]	Wang WY, Mei MJ, Gao YY, et al. Changes of brain structural network connection in Parkinson's disease patients with mild cognitive dysfunction: A study based on diffusion tensor imaging[J]. J Neurol, 2020, 267(4):933-943. doi: 10.1007/s00415-019-09645-x pmid: 31792673
[16]	Sebastiano G, Federica A, Elka S, et al. Structural brain connectome and cognitive impairment in Parkinson disease[J]. Radiology, 2017, 283(2):515-525. doi: 10.1148/radiol.2016160274 pmid: 27924721
[17]	Thais M, Li S, Elijah M, et al. Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study[J]. J Neurol, 2018, 265(7):1528-1539. doi: 10.1007/s00415-018-8873-0 pmid: 29696499
[18]	Naroa I, Carme J, Maria-Jose M, et al. Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: A voxel-based diffusion tensor imaging study[J]. Mov Disord, 2010, 25(12):1888-1894. doi: 10.1002/mds.23208 URL
[19]	梁红红. 帕金森病伴嗅觉障碍患者的弥散张量成像研究[D]. 郑州: 郑州大学, 2019.
[20]	Nigro P, Chiappiniello A, Simoni S, et al. Changes of olfactory tract in Parkinson's disease: A DTI tractography study[J]. Neuroradiology, 2021, 63(2):235-242. doi: 10.1007/s00234-020-02551-4
[21]	Hossein S, Mahsa D, Elaheh S, et al. Association of olfaction dysfunction with brain microstructure in prodromal Parkinson disease[J]. Neurol Sci, 2019, 40(2):283-291. doi: 10.1007/s10072-018-3629-2 pmid: 30386933
[22]	Zhang KY, Yu CS, Zhang YJ, et al. Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease[J]. Eur J Radiol, 2011, 77(2):269-273. doi: 10.1016/j.ejrad.2009.07.032 pmid: 19692193
[23]	Charalampos G, Marcel W, Nil D, et al. Olfactory impairment in Parkinson's disease studied with diffusion tensor and magnetization transfer imaging[J]. J Parkinsons Dis, 2017, 7(2):301-311.
[24]	Joshi N, Rolheiser TM, Fisk JD, et al. Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures,but not in substantia nigra[J]. J Neurol, 2017, 264(7):1497-1505. doi: 10.1007/s00415-017-8555-3 pmid: 28653210
[25]	Li ZH, Liu WG, Xiao CY, et al. Abnormal white matter microstructures in Parkinson's disease and comorbid depression: A whole-brain diffusion tensor imaging study[J]. Neurosci Lett, 2020, 735(1):135238. doi: 10.1016/j.neulet.2020.135238 URL
[26]	Osamu A, Hidenori Y, Kiyoto K, et al. Voxel-based analyses of gray/white matter volume and diffusion tensor data in major depression[J]. Psychiatry Res, 2010, 181(1):64-70. doi: 10.1016/j.pscychresns.2009.07.007 URL
[27]	Ning HX, Zhou H, Ren JR, et al. Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: A prospective, multicenter, randomized, double-blind, controlled clinical study[J]. J Transl Med, 2022, 20(1):357. doi: 10.1186/s12967-022-03551-z pmid: 35962349
[28]	Stéphanie M, Eric J, Isabelle Klein. Cognitive dysfunction and brain atrophy in Susac syndrome[J]. J Neurol, 2020, 267(4):994-1003. doi: 10.1007/s00415-019-09664-8 pmid: 31828475
[29]	Hu Xi, Qian L, Zhang Y, et al. Topological changes in white matter connectivity network in patients with Parkinson's disease and depression[J]. Brain Imaging Behav, 2020, 14(6):2559-2568. doi: 10.1007/s11682-019-00208-2
[30]	Ambra S, Birgit H. Sleep in Parkinson's disease[J]. Neuropsychopharmacology, 2020, 45(1):121-128. doi: 10.1038/s41386-019-0448-y pmid: 31234200
[31]	Andrew HF, Gordon WD, Michael JF, et al. Rapid eye movement sleep behavior disorder in Parkinson's disease: Magnetic resonance imaging study[J]. Mov Disord, 2013, 28(6):832-836. doi: 10.1002/mds.25367 URL
[32]	Lim JS, Shin SA, Lee JY, et al. Neural substrates of rapid eye movement sleep behavior disorder in Parkinson's disease[J]. Parkinsonism Relat Disord, 2016, 23(2):31-36. doi: 10.1016/j.parkreldis.2015.11.027 URL
[33]	Lisa O, Colette MS, Jodie RG. Tract-based spatial statistics reveal lower white matter integrity specific to idiopathic rapid eye movement sleep behavior disorder as a proxy for prodromal Parkinson's disease[J]. J Parkinsons Dis, 2019, 9(4):723-731.
[34]	Rafail M, Kuangyu S, Artemios A, et al. Brain neuroimaging of rapid eye movement sleep behavior disorder in Parkinson's disease: A systematic review[J]. J Parkinsons Dis, 2022, 12(1):69-83.
[35]	Zhou LC, Li GL, Zhang YY, et al. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder[J]. Brain, 2021, 144(5):1488-1497. doi: 10.1093/brain/awab039 pmid: 33880500

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Jiuxue, Li Na, Jin Wei, Wang Shuo, Chang Yajun, Wang Tianjun. Correlation between serum uric acid, homocysteine and cystatin C levels with motor symptoms and cognitive function in Parkinson's disease patients [J]. Clinical Focus, 2024, 39(2): 125-129.
[2]	. [J]. Clinical Focus, 2023, 38(9): 845-850.
[3]	. [J]. Clinical Focus, 2023, 38(9): 855-858.
[4]	Li Wenjun, Zhang Ce, Liu Junyan. Improving circulation aggravates the orthostatic hypotension in a patient with Parkinson's disease: A case report [J]. Clinical Focus, 2022, 37(10): 934-937.
[5]	. [J]. Clinical Focus, 2022, 37(5): 463-466.
[6]	Guo Chang, Shen Huinan, Sun Yimeng, Wang Dongyu. Correlation between blood lipid and homocysteine and cognitive impairment in Parkinson's disease [J]. Clinical Focus, 2022, 37(2): 128-132.
[7]	Zhao Hang;Ge Hanming;Liang Zhanhua;Wang Yan. Correlation analysis of individualized treatment compliance and disease progression in patients with Parkinson disease [J]. Clinical Focus, 2015, 30(5): 499-502.
[8]	SUN Lin-juan;XU Sheng-li;ZHOU Ming;MAO Li-jun;CHEN Biao. Protection of cysteamine on 1-methy1-4-phenylpyridinium induced SH-SY5Y in Parkinson's disease cell model by antioxidant [J]. Clinical Focus, 2014, 29(7): 740-743.
[9]	SUN Lin-juan;MAO Li-jun;XU Sheng-li;ZHOU Ming;CHEN Biao. Protection of cysteamine on dopaminergic neurons in Parkinson disease mice model by antioxidant [J]. Clinical Focus, 2013, 28(2): 181-0.
[10]	. [J]. Clinical Focus, 2012, 27(15): 1359-0.
[11]	ZENG Wen-jing;ZHANG Xiao-ying;LI Yan-yun;LIU Yan;LI Yan. Relationship between polymorphism of monoamine oxidase B gene and Parkinson disease in Xinjiang Uygurs [J]. Clinical Focus, 2012, 27(9): 764-766.
[12]	. [J]. CLINICAL FOCUS, 2011, 26(10): 888901-0.
[13]	. [J]. CLINICAL FOCUS, 2011, 26(5): 400-0.
[14]	. [J]. CLINICAL FOCUS, 2010, 25(21): 1931-0.
[15]	ZHANG Li;KONG Yan;XU Zhuan;CHEN Jian-hua;ZHANG Zheng-chun. Diagnostic value on pronton magnetic resonance spectroscopy of lentiform nucleus in Parkinson disease [J]. CLINICAL FOCUS, 2009, 24(13): 1115-1117.